Cargando…

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer

Introduction: The GenesWell Breast Cancer Test (BCT) is a recently developed multigene assay that predicts the risk of distant recurrence in patients with early breast cancer. Here, we analyzed the concordance of the BCT score with the Oncotype DX recurrence score (RS) for risk stratification in Asi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kwon, Mi Jeong, Lee, Jeong Eon, Jeong, Joon, Woo, Sang Uk, Han, Jinil, Kang, Byeong-il, Kim, Jee-Eun, Moon, Youngho, Lee, Sae Byul, Lee, Seonghoon, Choi, Yoon-La, Kwon, Youngmi, Song, Kyoung, Gong, Gyungyub, Shin, Young Kee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6670782/ https://www.ncbi.nlm.nih.gov/pubmed/31404265 http://dx.doi.org/10.3389/fonc.2019.00667

Ejemplares similares

Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2− Early Breast Cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2021)

BCT score predicts chemotherapy benefit in Asian patients with hormone receptor-positive, HER2-negative, lymph node-negative breast cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2018)

Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022)

Verification of a Western Nomogram for Predicting Oncotype DX™ Recurrence Scores in Korean Patients with Breast Cancer
por: Kim, Jae-Myung, et al.
Publicado: (2018)

The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016)

MiRNA expression deregulation correlates with the Oncotype DX(®) DCIS score
por: Loudig, Olivier, et al.
Publicado: (2022)

Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
por: Ünal, Çağlar, et al.
Publicado: (2023)

Ki 67 is a major, but not the sole determinant of Oncotype Dx recurrence score
por: Sahebjam, S, et al.
Publicado: (2011)

Correlation of Oncotype DX Recurrence Score with Histomorphology and Immunohistochemistry in over 500 Patients
por: Hanna, Matthew G., et al.
Publicado: (2017)

Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score
por: Lalani, Nafisha, et al.
Publicado: (2017)

A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
por: Davey, Matthew G., et al.
Publicado: (2022)

Association Between Phosphorylated Histone H3 and Oncotype DX Recurrence Scores in Breast Cancer
por: Lee, Lik Hang, et al.
Publicado: (2017)

Radiomics signature on 3T dynamic contrast-enhanced magnetic resonance imaging for estrogen receptor-positive invasive breast cancers: Preliminary results for correlation with Oncotype DX recurrence scores
por: Nam, Kyung Jin, et al.
Publicado: (2019)

A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer
por: Lee, Sae Byul, et al.
Publicado: (2019)

Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia
por: Collin, Lindsay J., et al.
Publicado: (2019)

Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer
por: Song, Ran, et al.
Publicado: (2023)

Low utility of Oncotype DX® in the clinic
por: Ricks‐Santi, Luisel J., et al.
Publicado: (2017)

BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score
por: Zarella, Mark D., et al.
Publicado: (2018)

Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®
por: Buus, Richard, et al.
Publicado: (2021)

MRI Radiomics and Machine Learning for the Prediction of Oncotype Dx Recurrence Score in Invasive Breast Cancer
por: Romeo, Valeria, et al.
Publicado: (2023)

Impact of the OncotypeDX score and HER2 RNA PCR levels on HER2-low IHC levels in primary and metastasized tumors
por: Feldman, Didi, et al.
Publicado: (2023)

A new molecular prognostic score for predicting the risk of distant metastasis in patients with HR+/HER2− early breast cancer
por: Gong, Gyungyub, et al.
Publicado: (2017)

Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis
por: Klein, Molly E, et al.
Publicado: (2013)

Impact of Oncotype DX Recurrence Score on Treatment Decisions: Results of a Prospective Multicenter Study in Turkey
por: Ozmen, Vahit, et al.
Publicado: (2016)

Oncotype DX: Where Does It Stand in India?
por: Batra, Atul, et al.
Publicado: (2019)

Impact of Oncotype DX Recurrence Score on the Patterns of Locoregional Recurrence in Breast Cancer (Korean Radiation Oncology Group 19-06)
por: Kim, Kyubo, et al.
Publicado: (2020)

Correlative Analysis of miRNA Expression and Oncotype Dx Recurrence Score in Estrogen Receptor Positive Breast Carcinomas
por: Emmadi, Rajyasree, et al.
Publicado: (2015)

Oncotype DX breast cancer recurrence score can be predicted with a novel nomogram using clinicopathologic data
por: Orucevic, Amila, et al.
Publicado: (2017)

Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
por: Aherne, T. M., et al.
Publicado: (2020)

Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score
por: Zhang, Michelle, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score(®) Test in Node-Negative Early Breast Cancer
por: Berdunov, Vladislav, et al.
Publicado: (2022)

Oncotype Dx Results in Multiple Primary Breast Cancers
por: Toole, Michael J., et al.
Publicado: (2014)

Spotlight on the utility of the Oncotype DX(®) breast cancer assay
por: Siow, Zhen Rong, et al.
Publicado: (2018)

Oncotype Dx Score, HER2 Low Expression, and Clinical Outcomes in Early-Stage Breast Cancer: A National Cancer Database Analysis
por: Roy, Arya Mariam, et al.
Publicado: (2023)

Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
por: Fried, Georgeta, et al.
Publicado: (2014)

Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy
por: Buus, Richard, et al.
Publicado: (2016)

Discordance between oncotype DX recurrence score and RSPC for predicting residual risk of recurrence in ER-positive breast cancer
por: Dodson, Andrew, et al.
Publicado: (2017)

Is radiomic MRI a feasible alternative to OncotypeDX(®) recurrence score testing? A systematic review and meta-analysis
por: Davey, M G, et al.
Publicado: (2021)

Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score
por: Li, Hongxiao, et al.
Publicado: (2022)

Breast Cancer with Low Recurrence Score on Oncotype DX(©): Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation
por: Zarbiv, Yonaton, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_da0lqrt6pipe3g2bt39fmakkpf